muramidase has been researched along with 1-3-dipropylxanthine* in 1 studies
1 other study(ies) available for muramidase and 1-3-dipropylxanthine
Article | Year |
---|---|
Effect of xanthine derivatives on chemotactic polypeptide-induced superoxide and enzyme release from human polymorphonuclear leucocytes.
1. We investigated the effects of new xanthine derivatives, 1-methyl-3-propyl xanthine (MPX) and 1,3-dipropyl xanthine (DPX), and several other xanthine derivatives on N-formyl-methionyl-leucyl-phenylalanine-induced superoxide and lysozyme release from human polymorphonuclear leucocytes (PMN). 2. MPX and DPX at low concentrations (10(-8) - 10(-9) mol/L) inhibited superoxide release from PMN by a maximum of 31.2 +/- 10.6% and 49.8 +/- 10.4% (mean +/- s.d.), respectively, and 10(-3) mol/L concentrations completely inhibited the release reactions (4.8 +/- 1.2 and 7.6 +/- 2.5% of control level). At 10(-5) mol/L, however, the inhibition did not occur (99.9 +/- 7.3 and 110.2 +/- 15.8% of control level). When PMN was pre-incubated with adenosine deaminase (ADA, 0.1 U/mL), superoxide release from PMN was inhibited in a dose-dependent manner by MPX and DPX and the interruption of the inhibition at 10(-5) mol/L was not observed. 3. Lysozyme release from PMN was inhibited by MPX at low concentrations (10(-7) - 10(-6) mol/L) and high concentrations (10(-3) mol/L). However 10(-4) mol/L of MPX facilitated the release (23.7 +/- 27.0%). When pretreated with ADA (0.1 U/mL), MPX suppressed lysozyme release in a dose-dependent manner and the facilitation of the release at 10(-4) mol/L was not observed. 4. When comparing effects of some other xanthine derivatives on superoxide release, the interruption of the inhibition of superoxide release at 10(-5) mol/L was commonly observed among xanthine derivatives with adenosine A2 antagonism.(ABSTRACT TRUNCATED AT 250 WORDS) Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Adenosine Deaminase; Chemotaxis, Leukocyte; Humans; Male; Muramidase; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Purinergic P1 Receptor Antagonists; Superoxides; Xanthines | 1993 |